{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:35Z","timestamp":1790391215856,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62220106006"],"award-info":[{"award-number":["62220106006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002855"],"award-info":[{"award-number":["82002855"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515120013"],"award-info":[{"award-number":["2021B1515120013"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.critrevonc.2023.104113","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T11:43:58Z","timestamp":1692877438000},"page":"104113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients"],"prefix":"10.1016","volume":"190","author":[{"given":"Yaofei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiong","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2023.104113_bib1","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score >\/= 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104113_bib5","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2017.03.037","article-title":"Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in checkmate 025","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib7","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.21873\/anticanres.13543","article-title":"Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies","volume":"39","author":"Fujita","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.critrevonc.2023.104113_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib9","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.jtho.2018.08.2027","article-title":"Atezolizumab treatment beyond progression in advanced NSCLC: results from the randomized, phase III OAK study","volume":"13","author":"Gandara","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2023.104113_bib11","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib12","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/COC.0000000000000449","article-title":"Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in epstein-barr virus-associated nasopharyngeal carcinoma","volume":"41","author":"Larbcharoensub","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib13","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Lee","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10637-020-00925-2","article-title":"Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study","volume":"38","author":"Li","year":"2020","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.critrevonc.2023.104113_bib15","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2023.104113_bib17","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib18","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1038\/bjc.2017.357","article-title":"Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review","volume":"117","author":"Prawira","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104113_bib19","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1002\/cncr.33626","article-title":"Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study","volume":"127","author":"Ruan","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2023.104113_bib20","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2023.104113_bib21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/2326-6066.CIR-14-0188","article-title":"Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab","volume":"3","author":"Taylor","year":"2015","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2023.104113_bib23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/mt.2012.184","article-title":"Cetuximab-mediated tumor regression depends on innate and adaptive immune responses","volume":"21","author":"Yang","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.critrevonc.2023.104113_bib25","first-page":"9","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)","author":"Yang","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104113_bib26","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104113_bib27","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842823002019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:50:41Z","timestamp":1760903441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842823002019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"alternative-id":["S1040842823002019"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104113","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent\/metastatic nasopharyngeal carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104113"}}